– Both single-agent XL092 and XL092 in combination with atezolizumab demonstrated encouraging efficacy and safety in a heavily pretreated patient population –– XL092 demonstrated preliminary clinical activity similar to that observed with cabozantinib in phase 1 across a range of solid tumors and dose levels, with a.
Exelixis (EXEL) Announces More Detailed Results of Phase 3 COSMIC-313 Trial in Advanced Kidney Cancer at ESMO streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
– Cabozantinib in combination with nivolumab and ipilimumab significantly reduced the risk of disease progression or death compared with the combination of nivolumab and ipilimumab –– Median progression-free survival was not yet reached with the combination of cabozantinib, nivolumab and ipilimumab versus 11.3 month.
08.09.2022 - Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from COSMIC-313, an ongoing phase 3 pivotal trial evaluating the combination of cabozantinib (CABOMETYX), nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in .
- Cabozantinib in combination with nivolumab and ipilimumab significantly reduced the risk of disease progression or death compared with the combination of nivolumab and ipilimumab - - Median progression-free